Literature DB >> 27987149

Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.

Kerstin F Gerer1, Stefanie Hoyer1, Jan Dörrie1, Niels Schaft2.   

Abstract

Electroporation (EP) of mRNA into human cells is a broadly applicable method to transiently express proteins of choice in a variety of different cell types. We have spent more than a decade to optimize and adapt this method, first for antigen-loading of dendritic cells (DCs), and subsequently for T cells, B cells, bulk PBMCs, and several cell lines. In this regard, antigens were introduced, processed, and presented in context of MHC class I and II. Next to that, functional proteins like adhesion receptors, T-cell receptors (TCRs), chimeric antigen receptors (CARs), constitutively active signal transducers, and others were successfully expressed. We have also established this protocol under full GMP compliance as part of a manufacturing license to produce mRNA-electroporated DCs for therapeutic vaccination in clinical trials. Therefore, we here want to share our universal mRNA electroporation protocol and the experience we have gathered with this method. The advantages of the transfection method presented here are: (1) easy adaptation to different cell types, (2) scalability from 106 to approximately 108 cells per shot, (3) high transfection efficiency (80-99 %), (4) homogenous protein expression, (5) GMP compliance if the EP is performed in a class A clean room, and (6) no transgene integration into the genome. The provided protocol involves: Opti-MEM® as EP medium, a square-wave pulse with 500 V, and 4 mm cuvettes. To adapt the protocol to differently sized cells, simply the pulse time is altered. Next to the basic protocol, we also provide an extensive list of hints and tricks, which in our opinion are of great value for everyone who intends to use this transfection technique.

Entities:  

Keywords:  Antigen expression; B cell; CAR; GMP; Immunotherapy; Monocyte-derived DC (moDC); Protein expression; T cell; TCR; mRNA electroporation

Mesh:

Substances:

Year:  2017        PMID: 27987149     DOI: 10.1007/978-1-4939-6481-9_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  16 in total

1.  NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease.

Authors:  Suk See De Ravin; Julie Brault; Ronald J Meis; Linhong Li; Narda Theobald; Aylin C Bonifacino; Hong Lei; Taylor Q Liu; Sherry Koontz; Cristina Corsino; Marissa A Zarakas; Jigar V Desai; Aaron B Clark; Uimook Choi; Mark E Metzger; Kamille West; Steven L Highfill; Elizabeth Kang; Douglas B Kuhns; Michail S Lionakis; David F Stroncek; Cynthia E Dunbar; John F Tisdale; Robert E Donahue; Gary A Dahl; Harry L Malech
Journal:  Blood Adv       Date:  2020-12-08

Review 2.  Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.

Authors:  Siddharth Patel; Avathamsa Athirasala; Paula P Menezes; N Ashwanikumar; Ting Zou; Gaurav Sahay; Luiz E Bertassoni
Journal:  Tissue Eng Part A       Date:  2018-06-07       Impact factor: 3.845

Review 3.  mRNA Vaccines: Why Is the Biology of Retroposition Ignored?

Authors:  Tomislav Domazet-Lošo
Journal:  Genes (Basel)       Date:  2022-04-20       Impact factor: 4.141

4.  Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.

Authors:  Kerstin F Gerer; Michael Erdmann; Sine R Hadrup; Rikke Lyngaa; Lena-Marie Martin; Reinhard E Voll; Beatrice Schuler-Thurner; Gerold Schuler; Niels Schaft; Stefanie Hoyer; Jan Dörrie
Journal:  Ther Adv Med Oncol       Date:  2017-06-13       Impact factor: 8.168

5.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

6.  Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC.

Authors:  Stefan Schierer; Christian Ostalecki; Elisabeth Zinser; Ricarda Lamprecht; Bianca Plosnita; Lena Stich; Jan Dörrie; Manfred B Lutz; Gerold Schuler; Andreas S Baur
Journal:  Life Sci Alliance       Date:  2018-12-03

Review 7.  Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy.

Authors:  Mouldy Sioud
Journal:  Cancers (Basel)       Date:  2019-02-03       Impact factor: 6.639

8.  Autophagic degradation of lamins facilitates the nuclear egress of herpes simplex virus type 1.

Authors:  Aykut Turan; Linda Grosche; Adalbert Krawczyk; Petra Mühl-Zürbes; Christina Drassner; Alexandra Düthorn; Mirko Kummer; Mike Hasenberg; Sylvia Voortmann; Holger Jastrow; Jan Dörrie; Niels Schaft; Max Kraner; Katinka Döhner; Beate Sodeik; Alexander Steinkasserer; Christiane Silke Heilingloh
Journal:  J Cell Biol       Date:  2018-12-26       Impact factor: 10.539

9.  NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells.

Authors:  Naomi C Bosch; Reinhard E Voll; Caroline J Voskens; Stefanie Gross; Barbara Seliger; Gerold Schuler; Niels Schaft; Jan Dörrie
Journal:  Ther Adv Med Oncol       Date:  2019-12-11       Impact factor: 8.168

10.  BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.

Authors:  Jan Dörrie; Lek Babalija; Stefanie Hoyer; Kerstin F Gerer; Gerold Schuler; Lucie Heinzerling; Niels Schaft
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.